• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Aptose Biosciences Inc.

    4/21/25 5:28:56 PM ET
    $APTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APTO alert in real time by email
    8-K
    CA false 0000882361 0000882361 2025-04-15 2025-04-15
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 15, 2025

     

     

    APTOSE BIOSCIENCES INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Canada   001-32001   98-1136802
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (I.R.S. Employer
    Identification No.)

    66 Wellington Street West, Suite 5300

    TD Bank Tower, Box 48

    Toronto, Ontario M5K 1E6

    Canada

    (Address of Principal Executive Offices) (Zip Code)

    (647) 479-9828

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Shares, no par value   APTO   The Nasdaq Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 4.01. Changes in Registrant’s Certifying Accountant.

    On April 15, 2025, KPMG LLP (“KPMG”), the current independent registered public accounting firm of Aptose Biosciences Inc. (the “Company”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two fiscal quarters of 2025. The Company has initiated a process to appoint a new independent registered public accounting firm.

    KPMG did not seek the Company’s consent to its decision to not stand for re-appointment as the Company’s independent registered public accounting firm. As a result, neither the Company’s Board of Directors nor the Audit Committee of the Company’s Board of Directors participated in KPMG’s decision.

    KPMG issued unqualified reports on the Company’s consolidated financial statements for the fiscal years ended December 31, 2024 and 2023. The Company is a “smaller reporting company”, so KPMG was not required to prepare reports on the effectiveness of the Company’s internal control over financial reporting for the years ended December 31, 2024 and 2023.

    During the Company’s fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through April 15, 2025, there were no: (1) “disagreements” between the Company and KPMG within the meaning of Item 304(a)(1)(iv) of Regulation S-K on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to their satisfaction would have caused them to make reference in connection with their opinion to the subject matter of the disagreement, or (2) “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K, except that KPMG communicated to the Company its views regarding the material weakness in its internal control over financial reporting as disclosed in Part II, Item 9A of the Company’s Form 10-K for the fiscal year ended December 31, 2024 pertaining to its accounting for complex financial instruments, specifically with regards to warrants. The Company has authorized KPMG to respond fully to the inquiries of the successor independent registered public accounting firm, once one is engaged.

    In accordance with Item 304(a)(3) of Regulation S-K, the Company provided KPMG with a copy of the disclosures it is making in this Current Report on Form 8-K and requested from KPMG a letter addressed to the Securities and Exchange Commission indicating whether it agrees with such disclosures. A copy of KPMG’s letter dated April 21, 2025 is attached as Exhibit 16.1 hereto.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit Number    Description
    16.1    Letter from KPMG LLP to the Securities and Exchange Commission
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Aptose Biosciences Inc.
    Date: April 21, 2025     By:  

    /s/ William G. Rice

          William G. Rice, Ph.D.
          President and Chief Executive Officer
    Get the next $APTO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APTO

    DatePrice TargetRatingAnalyst
    12/21/2021$14.00 → $12.00Buy
    HC Wainwright & Co.
    11/12/2021$9.00 → $14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

      Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS, OTC:APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose's Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed with a 40 mg or 80 mg dose of tuspe

      5/5/25 7:00:00 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose Announces Auditor Not Standing for Re-Appointment

      SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the "KPMG"), informed the Company that it will not stand for re-appointment for the Company's 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two fiscal quarters of 2025. The Company

      4/23/25 5:00:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

      SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025. Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with Aptose please contact your conference repre

      4/23/25 7:30:00 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Leadership Updates

    Live Leadership Updates

    See more
    • NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer

      NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Greg Chow as Chief Financial and Business Officer (CFBO), effective immediately. Greg is an experienced executive with over 25 years of corporate finance, capital markets, investment banking, financial accounting, drug development operations, and business development experience. Over th

      8/1/24 7:00:00 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose Announces Results from Annual and Special Meeting of Shareholders

      SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 18, 2024 (the "Meeting"). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Company entitled to be voted, were represented by shareholders present or represented by proxy at the Meeting. The Company is pleased to announce that all of the nominees listed in the proxy

      6/18/24 5:30:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

      SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer. With a healthcare tenure of more than 25 years, Mr. Payne has held several CFO and senior management positions at biotech companies in addition to finance and accounting roles, and has overseen legal, corporate development and licensing functions. During his career, he has execu

      11/30/23 4:59:54 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    SEC Filings

    See more
    • Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aptose Biosciences Inc. (0000882361) (Filer)

      4/23/25 5:00:09 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRER14A filed by Aptose Biosciences Inc.

      PRER14A - Aptose Biosciences Inc. (0000882361) (Filer)

      4/23/25 6:04:58 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Aptose Biosciences Inc.

      8-K - Aptose Biosciences Inc. (0000882361) (Filer)

      4/21/25 5:28:56 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Aptose Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Aptose Biosciences with a rating of Buy and set a new price target of $12.00 from $14.00 previously

      12/21/21 5:27:22 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Aptose Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Aptose Biosciences with a rating of Buy and set a new price target of $14.00 from $9.00 previously

      11/12/21 6:08:40 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Aptose Biosciences with a new price target

      Oppenheimer reiterated coverage of Aptose Biosciences with a rating of Outperform and set a new price target of $9.00 from $8.00 previously

      3/24/21 6:57:14 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Hanmi Pharmaceutical Co., Ltd. claimed ownership of 508,710 shares (SEC Form 3)

      3 - Aptose Biosciences Inc. (0000882361) (Issuer)

      3/20/25 8:54:45 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chair, President & CEO Rice William G. bought $20,000 worth of shares (100,000 units at $0.20), increasing direct ownership by 19% to 613,252 units (SEC Form 4)

      4 - Aptose Biosciences Inc. (0000882361) (Issuer)

      11/26/24 6:56:32 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Ledru Philippe

      4 - Aptose Biosciences Inc. (0000882361) (Issuer)

      5/10/24 11:35:32 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chair, President & CEO Rice William G. bought $20,000 worth of shares (100,000 units at $0.20), increasing direct ownership by 19% to 613,252 units (SEC Form 4)

      4 - Aptose Biosciences Inc. (0000882361) (Issuer)

      11/26/24 6:56:32 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Seizinger Bernd R. bought $53,380 worth of shares (17,000 units at $3.14)

      4 - Aptose Biosciences Inc. (0000882361) (Issuer)

      9/25/23 5:03:39 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Financials

    Live finance-specific insights

    See more
    • Aptose Reports Results for the First Quarter 2024

      TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today   SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024. The Company will p

      5/14/24 4:01:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

      SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company's Chief Medical Officer and resident Key Opinion Leader, will review a selection of slides and discuss the clinical strategy for advancing the Company's lead asset tuspetinib (TUS) in a TUS+VEN+HMA triplet drug combination for the frontline treatmen

      5/6/24 4:30:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

      SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:link(https://register.vevent.com/register/BIe69f08fc83634a6aa38bf7081d82c6a2)   *Analysts interested in participating in the question-and-answer sess

      3/18/24 4:30:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aptose Biosciences Inc.

      SC 13G - Aptose Biosciences Inc. (0000882361) (Subject)

      11/14/24 3:22:02 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Aptose Biosciences Inc. (Amendment)

      SC 13D/A - Aptose Biosciences Inc. (0000882361) (Subject)

      4/26/24 12:54:08 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Aptose Biosciences Inc. (Amendment)

      SC 13G/A - Aptose Biosciences Inc. (0000882361) (Subject)

      2/14/24 4:51:40 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care